ReviewCancers2023
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Solid Tumors.CPT: pharmacometrics & systems pharmacology · 2025Trial
- Translational and Implementation Barrier in the Management of Biliary Tract Cancer: Diagnostic, Molecular, Therapeutic, and Patient-Centered Challenges.Journal of gastroenterology and hepatology · 2026Review
- Generation of a distal lung cancer organoid model using oncogenic ret-expressing induced pluripotent stem cells.iScience · 2026Article
- Article
- RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.International journal of molecular sciences · 2026Review
- Molecular Characterisations and the Association with Clinical Factors inCancer management and research · 2026Article
- Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer.Frontiers in oncology · 2026Article
- Review
- Article
- Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors.Cancer research communications · 2025Article
- Age-Specific Risk of Second Primary Malignant Neoplasm After Radioactive Iodine Treatment for Differentiated Thyroid Cancer.JAMA otolaryngology-- head & neck surgery · 2025Article
- Tumour-agnostic kinase inhibitors.Nature reviews. Drug discovery · 2025Review
- The present and future of precision oncology and tumor-agnostic therapeutic approaches.The oncologist · 2025Review
- Kinome profiling reveals pathogenic variant specific protein signalling networks in MEN2 children with Medullary Thyroid Cancer.NPJ precision oncology · 2025Article
- The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis.Translational oncology · 2025Article
- Genomic testing for RET in the clinic: UK and global perspective.Endocrine-related cancer · 2025Review
- Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology.Molecular oncology · 2025Article
- Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications.International journal of molecular sciences · 2025Review
- Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions.Cancer · 2025Review
- Agnostic Biomarkers in Molecular Pathology.Journal of clinical practice and research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.